Cirrhosis of the Liver-Artichoke Bud / Sarsaparilla Root Extract (ASE)

[Guest guest]

Published in The Townsend Magazine for Doctor's & Patients

 

Decrease Cirrhosis of the Liver-

By Extreme Health and Dr. C. Cochran

 

http://www.extremehealth-autism.com/press6.htm

 

Artichoke Bud / Sarsaparilla Root Extract (ASE)

 

This extremely effective combination of ingredients has Double Blind

Studies to verify the decreases in degenerative liver damage in

patients with chronic liver disease (cirrhosis of the liver) in as

few as 30 to 90 days.

 

This combination has proven studies for

detoxifying the liver, normalizing liver metabolism and preventing

further liver damage due to internal and external toxins like

alcohol, cigarettes and environmental poisons

 

DESCRIPTION

The artichoke bud / sarsaparilla extract is an entirely unique

complex of phytochemicals extracted from the bud of a hybrid

artichoke plant (Cynara floridanum) and the root of the sarsaparilla

plant (Smilax officinalis).

 

The proprietary extraction process uses a method in which all plant

materials are first combined, macerated, and put into a distilled

water / ethanol solvent. This allows the plant materials to interact

within the solvent resulting in an exceptional, health-providing

formulation of polyphenols and flavonoids.

 

FEATURES

· ASE is a complex of liver-supportive, detoxifying phytonutrients

that are extracted using a proprietary, two-step method. It is

unlike anything in the marketplace today. Partial analysis has

revealed a quite extraordinary complex of flavonoids, including

quercetin, rutin, - (+) catechin, hesperidin, kaempferol,

isorhamnetin, cynarin, silymarin, caffeic acid, and chlorogenic

acid. Phytosterols, including ß-sitosterol, campesterol, and

stigmasterol, have also been detected.

 

· ASE has been created by combining materials from two plants that

have been historically used as liver regenerative, detoxifying, and

blood-purifying agents.

 

BENEFITS

· ASE has been used to normalize liver and gall bladder function in

clinical settings for over 20 years.

· ASE is well tolerated and completely safe with no known side

effects. Contraindications include allergies to artichoke or

sarsaparilla and biliary duct obstruction, such as with gallstones.

· ASE functions as a gentle detoxifier; digestive aid; and a liver,

gall bladder, and bowel normalizer.

 

PHYSIOLOGY

· Extracts of artichoke leaf have been found to stimulate bile

production in the liver and bile release from the gall bladder, and

thus found effective in helping to eliminate toxic substances,

normalizing blood cholesterol levels, lowering blood lipids, and

providing liver protective qualities.

· The root of the sarsaparilla plant is considered by European

physicians to be an alterative tonic, blood purifier, diuretic

(increases urine output) and diaphoretic (increases perspiration).

 

CLINICAL INDICATIONS

· Inhabit or work in toxic environments

· Abnormal liver enzymes or history of liver disease, including

alcoholic liver disease

· For those who smoke, drink alcoholic beverages, or take drugs

· Abnormal blood lipids (cholesterol and triglycerides)

· Digestive or bowel disorders, very effective for irritable bowel

syndrome

· Those with surgically removed gall bladders (cholecystectomy)

· Hepatitis patients

· Overweight patients, and during weight loss programs

· Skin disorders, including psoriasis and adult onset acne

 

1st Double Blind Study

 

INTERPRETATION OF RESULTS OBTAINED IN A DOUBLE BLIND TEST MADE IN

THE GENERAL HOSPITAL MEXICO WITH THE PRODUCT LIVER SUPPORT ON

PATIENTS HAVING CHRONIC ALCOHOLIC HEPATIC DISEASE.

 

 

In order to analyze carefully the results of this study, it is

necessary to know the importance of the two clinical and laboratory

parameters intervening in the calculations of Orrego and Maddrey

Indexes.

 

We will compare the results of the parameters, the placebo control

and the Liver Support groups on both indexes. The results are

presented as percentages of recovery and are obtained from the data

obtained from each group of 30 patients, we will get an average of

those results at the beginning and at the end of the study. Both

averages will give us a final recovery compared to the initial

values. This way we may demonstrate the effectiveness of Liver

Support.

 

DEFINTIONS AND RESULTS OF PARAMETERS

 

ASCITES- Effusion and accumulation of serous fluid in the abdominal

cavity. experimental group (Liver Support) experienced a 28.8%

reduction of ascites while the placebo group experienced no change

The.

 

ENCEPHALOPATHY- a DEGENERATIVE DISEASE OF THE BRAIN. Hepatic

encephalopathy- a condition usually occurring secondarily to

advanced disease of the liver. It is marked by disturbances of

consciousness that may progress to deep coma (hepatic coma),

psychiatric changes of varying degree, flapping tremor and fetor

hepaticas. Also called portal-systemic encephalopathy. Patients on

Liver Support experienced a 34.55% reduction of hepatic

encephalopathy. The placebo group experienced a 5.5% reduction.

 

SPLENOMEGALIA- Enlargement of the spleen. An 18.18% reduction was

observed in the Liver Support group and a 55% reduction was observed

in the placebo group.

 

WEAKNESS- Lacking physical strength or vigor marked by asthenia,

atony, cardiasthena, enervation, fatigue and lassitude. The Liver

Support group experienced an 83.45% decrease in the incidence of

weakness while the placebo group reported no change.

 

PERIPHERAL EDEMA- A condition in which the body tissues contain an

excess amount of fluid. The Liver Support Group experienced an

11.10% reduction in peripheral edema while the placebo group had a

0.69% reduction.

 

HEMORRHAGES- Bleeding. This was one of the most important benefits

observed in the Liver Support group. The Liver Support group had an

89.41% reduction in hemorrhages while the placebo had a 31%

reduction.

 

ANOREXIA- Loss of appetite. Seen in depression, malaise,

commencement of fevers and illness, also in disorders of the

alimentary tract, especially of the stomach, and as a result of

alcoholic excess and drug addiction. Anorexia was diminished by

86.07% in the Liver Support group. There was no change in the

placebo group.

 

TOTAL BILIRUBIN LEVEL - The predominant pigment of human bile. Total

serum bilirubin may be increased in cirrhosis of the liver and acute

viral hepatitis. The Liver Support group obtained 25.11% reduction

in bilirubin, whereas the placebo group had a 7.2% increase.

 

OGT - (Oxalacetic Glutamic Transaminase). It is distributed all over

body tissue, especially in the heart and liver. Fewer amounts are

found in the spleen, pancreas, kidneys, lungs and brain. Any lesion

of a tissue leads to the secretion of this enzyme to the blood

stream. The activity of OGT is risen under hepatic necrosis,

cirrhosis of the liver or hepatic metastasis. In those patients who

received Liver Support this level diminished 22.56% in only 15 days

of treatment and in the placebo group it diminished 8.51%.

 

PROTHROMBINE TIME - A test of clotting time made by determining the

time for clotting to occur after thromboplastin and calcium are

added to decalcified plasma. There was 30.82% reduction in

prothrombin time for Liver Support patients, whereas the placebo

group's time increased 1.25%. This is very important data, because

it means that Liver Support helps the healing of wounds faster.

 

SERUM ALBUMIN - One of a group of simple proteins widely distributed

in tissues. Albumin is a constituent of blood. Low levels of albumin

in blood plasma are associated with a pathologic condition of the

liver. The Liver Support group experienced an increase of 8.85% of

total albumin levels while the placebo group experienced a 5.35%

increase.

 

2nd Double Blind Study

 

COMPARATIVE STUDY BETWEEN A COMPLEX OF

FLAVONOIDS AND POLYPHENOLS CREATED FROM

EXTRACTS OF ARTICHOKE AND SARSAPRILLA AND A

PLACEBO IN ALCOHOL RELATED LIVER DISEASE

 

DECEMBER 12, 1998

 

In a previous study, completed over two years ago in this same

hospital, an extract of artichoke (Cynara Floridanum) and

sarsaparilla (Smilax Aristolochiaefolia) was evaluated in addressing

the symptoms related to alcoholic liver disease.

 

This study was accomplished over a fifteen-day period with

exceptional results.

Because of these results noted over a very short period of time, the

hospital researchers were anxious to set up the same study over a

longer period (30 days). Please refer to the July 3, 1996, study for

descriptions of symptoms and study parameters. Results of this study

are as follows:

 

ASCITES

A 72.38% reduction of the accumulation of serous abdominal fluid was

noted in the treated group. The placebo saw a 6.35% increase in

abdominal fluid.

 

ENCEPHALOPATHY

A 66.08% reduction of symptoms related to encephalopathy was noted

in the treated group. The placebo group saw a 12.24% increase in

these symptoms.

 

HEPATOMEGALY

The treated group experienced a 93.33% reduction in enlarged livers.

In the placebo group their livers continued to enlarge by another

7.14%.

 

SPLENOMEGALY

An 88.40% reduction in spleen enlargement was noted with the treated

group. The placebo group worsened by 11.54%.

 

WEAKNESS

The treated group noted a 73.64% increase in strength. There was a

decrease in muscle strength by 7.41% in the placebo group.

 

PERIPHERAL EDEMA

Edema in the extremities of the treated patients decreased by

48.21%. There was no change in the placebo group.

 

HEMORRHAGES

The treated group noted a 100% decrease in capillary hemorrhaging in

the skin, gums, and nasal membranes. The placebo group saw an

increase of 28.57% in hemorrhaging.

 

ANOREXIA

Loss of appetite decreased in the treated group by 76.98%. The

placebo group noted a decrease of 3.70%.

 

ABDOMINAL WALL VEINS

The treated group experienced a 60.62% decrease in tortuous veins in

the abdomen related to ascites. The placebo group saw a 3.33%

decrease.

 

PALMAR ERYTHEMA

The treated group noted a 26.67% decrease in red and swollen palms.

In the placebo group there was no change.

 

TELANGIECTASIA

A 60.00% reduction in vascular lesions was noted in the treated

group. A 3.33%

reduction was seen in the placebo group.

 

TOTAL BILIRUBIN

The treated group noted a reduction of total bilirubin by 38.95%.

The placebo group increased by 5.68%.

 

ALKALINE PHOSPHATASE

The treated group obtained 25.91% reduction in alkaline phosphates.

There was an 11.69% increase in the placebo group.

 

SERUM GLUTAMIC OXALCETIC TRANSAMINASE (SGOT)

The treated group noted a decrease of 23.83% in SGOT levels. The

placebo group experienced a worsening of 11.71%.

 

PROTHROMBIN TIME

A 42.00% reduction in clotting time was noted with the treated

group. An increase in clotting time was noted in the placebo group

of 6.60%.

 

SERUM ALBUMIN

An increase of 37.27% in serum albumin was noted in the treated

group. There was a decrease in the placebo group of 1.95%.

 

GAMMA GLUTAMYL TRANSPEPTIDASE (GGT)

The treated group noted a reduction of 23.79% in GGT. The placebo

group experienced an increase of 9.92%.

 

 

DR. CHARLES COCHRAN

 

SCIENTIFIC RESEARCH

Beneficial effects of flavonoids have been described for

successfully treating many health conditions, including cancer,

viral infections, diabetes, headaches, liver disease, ulcers, and

allergies.

 

They can also bind to enzymes and DNA, chelate heavy

metals, and play a role in electron transport.

Van, Acker, S. et al; Structural Aspects of Antioxidant Activity of

Flavonoids, Flavonoids in Health and Disease, Rice-Evans, C. editor,

Marcel Dekker, Inc. 1998.

 

It is highly unlikely that the therapeutic value of medicinal plants

is due to either one flavonoid or an entire flavonoid fraction

alone.

Packer, Lester et al; Ginkgo biloba Extract Egb 761; Biological

Actions, Antioxidant Activity, and Regulation of Nitric Oxide

Synthase, Flavonoids in Health and Disease, Rice-Evans, C. editor

Marcel Dekker, Inc. 1998.

 

Phytosterols are plant fats. Plants do not contain cholesterol, but

phytosterols play a similar role in plants to that of cholesterol in

humans, primarily the forming of cell membrane structures, sources

of fuel for storage and transport, and protective surface coatings.

The most common plant sterols are ß-sitosterol, campesterol, and

stigmasterol.

 

Recent studies have shown that phytosterols have

antihyperglycemic and insulin-releasing effects, anti-inflammatory

and antipyretic activities, and important immune regulating and T-

cell proliferative activities.

 

Ivorra MD, et al; Antihyperglycemic and Insulin-releasing Effects of

ß-sitosterol 3-B-glucoside and Its Aglycone, ß-sitosterol, Archives

of the International Phamnacodyn, V. 296, April 1988, 224-231.

Gupta R. et al; Anti-inflammatory and Antipyretic Activities of ß-

sitosterol, Planta Medica (Journal of Plant Medicine) V. 39, 1980,

157-163.

Pegel, Karl, The Importance of Sitosterol and Sitosterolin in Human

and Animal Nutrition, South African Journal of Science, V. 93, June

1997, 263-268.

 

Extracts of the artichoke leaf stimulates bile production in the

liver and increased bile release from the gall bladder, and thus has

been effective in helping to eliminate toxic substances, normalizing

blood cholesterol levels, lowering blood lipids, and providing liver

protective qualities.

 

Adzet T, et al; Hepatoprotective Activity of Polyphenolic Compounds

from Cynara Scolymnus Against CC14 Toxicity in Isolated Rat

Hepatocytes, Journal of Natural Products, 50: 612, 1987.

Gebhart R; Inhibition of Cholesterol Biosynthesis in Primary

Cultured Rat Hepatocytes by Artichoke Extracts. J Pharmacol Exp Ther

286; 3, 1998.

 

Fintelmann V; Therapeutic Profile and Mechanism of Action of

Artichoke Leaf Extract; Hypolipemic, Antioxidant, Hepatoprotective

and Choleretic Properties. Phytomedicine, 1996. Supplement 1:50.

Kirchoff R, et al; Increase in Choleresis By Means of Artichoke

Extract. Results of a Randomized Placebo-controlled Double-blind

study. Phytomedicine 1: 107, 1994.

 

European physicians consider sarsaparilla root as an alterative

tonic, blood purifier, diuretic, and diaphoretic.

 

With its clinical uses as a blood purifier, it was registered as an

official herb in

the U.S. Pharmacopoeia as a treatment for syphilis from 1820 to

1910. Clinical observations in China demonstrated that sarsaparilla

is effective in about 90% of acute cases and 50% of chronic cases of

syphilis. In 1942 it was shown to dramatically improve psoriasis,

and in the 1950's the antibiotic properties of sarsaparilla were

documented.

 

An herbal Saudi Arabian drug created from sarsaparilla has been used

for many years to treat rheumatism and various forms of arthritis.

Further studies showed that sarsaparilla inhibited carrageenan-

induced inflammation in rats.

 

Recent research from China has shown that an extract of

sarsaparilla was able to prevent immunological

liver damage. And three studies performed between 1994 and 1999,

have shown that extracts of sarsaparilla have snake venom inhibitory

activity.

 

Hobbs, C; Sarsaparilla, A Literature Review, HerbalGram, No. 17,

1988.

Lung, A, Foster, S; Encyclopedia of Common Natural Ingredients, John

Wiley & Sons, Inc. New York, 1996.

Thurman, FM; The Treatment of Psoriasis with Sarsaparilla Compound,

New England Journal of Medicine, 337, 128-133, 1942.

D'Amico, ML; Ricerche Sulla Presenza Di Sostanze Ad Azione

Antiiotica Nelle Piante Superiori, Fitoterapia, 21(1), 77-79, 1950.

Fitzpatrick, FK; Plant Substances Active Against Mycobacterium

Tuberculosis, Antibiotics and Chemotherapy, 4(5), 528-536, 1954.

Ageel, AM et al; Experimental Studies on Antirheumatic Crude Drugs

Used in Saudi Traditional Medicine, College of Pharmacy, Kind Daud

University, Riyadh, Saudi Arabia, Drugs Exp Clin Res 1989, 15(:

369-372.

Chen, T, et al; A New Flavanone Isolated From Rhizoma Smilacis

Glabrae and the Structural Requirements of Its Derivatives for

Preventing Immunological Hepatocyte Damage. Planta Med 1999, Feb;65

(1):56-59.

Alam MI, et al; Isolation, Purification and Partial Characterization

of Viper Venom Inhibiting Factor from the Root Extract of the Indian

Medicinal Plant Sarsaparilla, Toxicon, 1994, Dec;32(12): 1551-1557.

Castro O, et al: Neutralization of the Hemorrhagic Effect Induced by

Bothrops Asper (Serpentes Viperidae) Venom with Tropical Plant

Extracts, Rev Biol Trop 1999, Sep: 47(3): 605-616.

 

 

COMPARISON WITH OTHER NATURAL SUBSTANCES

Oftentimes ASE is compared with extracts of milk thistle, alpha-

lipoic acid, other artichoke extracts, N-acetyl cysteine, and

nucleic acids in its effectiveness to support liver detoxification

and aid in liver disease. Since no side-by-side studies have been

performed comparing these nutrients, we cannot say that anyone of

these natural, very valuable substances is better than the other.

However, clinically we have found that by combing the ASE with any

of the above-mentioned nutrients, results can be enhanced

tremendously. Another very effective common method is to alternate

nutrients. This keeps the body from developing sensitivities or

desensitivities to any one nutrient during prolonged treatments.

 

For further information

http://www.extremehealth-autism.com/press6.htm